In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis
Veronique Neumeister(Yale University), David L. Rimm(Yale University), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Seema Agarwal(Girls Incorporated), Robert L. Camp
Cited by 154
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753